UNSPSC 51123800: Antiarrythmic guanidines

This classification denotes iminourea derivatives based in whole or part on guanidine or CH5N3, substances called guanidines, that prevent or treat irregular heartbeat, disturbances of normal rhythmic heart beating, or normal operation of myocardial contraction, thus the term ANTIARRYTHMIC GUANIDINES.

UNSPSC 51123800 Antiarrhythmic guanidines, a Class code, encompasses emergency and critical-care cardiac medications that state and local governments procure for fire-rescue services, health agencies, and pharmacy benefit programs. The code captures advanced life support medications supplied to first-responder systems and state health programs, with vendors supplying specific drug formulations (labetalol, epinephrine, adenosine, diltiazem, and generics across broader therapeutic categories) through competitive sealed-bid and cooperative purchasing vehicles. Issuing bodies span city fire departments, state health and human services commissions, and multistate cooperative purchasing consortia; Tampa Fire Rescue, the Texas Health and Human Services Commission, and the Minnesota Department of Administration represent the recent activity types. The work involves furnishing medications in specified quantities and unit strengths, managing expiration-date compliance, arranging delivery and replacement logistics, and maintaining regulatory certifications including Good Manufacturing Practices compliance and Drug Supply Chain Security Act adherence.

Recent activity clusters in Florida, Texas, and Minnesota. The City of Tampa posted an IFB (Solicitation 26P00188) on April 24, 2026, for Advanced Life Support Medications to supply 370 units of labetalol HCl, 1,810 units of epinephrine, 330 units of adenosine, and 1,020 units of diltiazem with a nine-month minimum expiration window and ten-day delivery; the estimated contract value was $40,000.00, with a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount. The Texas Health and Human Services Commission issued RFI No. HHS0017013 in March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting capacity and value-based agreement structures outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, requiring vendor certification of cGMP compliance, DSCSA adherence, relationships with authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), and insurance coverage including $5,000,000 commercial general liability with a two-year contract term and optional extensions.